LNCaP In Vitro High Content Screening (HCS) Assay

This assay is to provide LNCaP-based In Vitro High Content Screening (HCS) Assay to accelerate our client's oncology projects. The assay will be customized according to the specific requirements. Please contact our scientists to discuss more details.

LNCaP

Human

The LNCaP cell line was originally isolated from the lymph node of a patient with metastatic prostate cancer. Many cell lines have been derived from LNCaP by selective pressures to study different aspects of prostate cancer progression.

Prostate Adenocarcinoma

Oncology

In Vitro High Content Screening (HCS) Assay

LNCaP-cell based In Vitro High Content Screening (HCS) Assay

HCS is one of the latest techniques used in cancer drug discovery programs. Unlike traditional HTS platforms, HCS provides more visual information about the experiment being conducted. HCS is a very powerful tool for multivariate and quantitative data analysis. Cellbased HCS systems have also gained much attention in biological research and cancer drug discovery programs.

High-throughput Screening, High Content Screening and Reporter Gene Assays